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Among efforts to establish an appropriate animal model to test 
this novel hypothesis, two most recent studies reported promising 
results, using an established animal model featured with selective 
damage in the white matter of the central nervous system (CNS) 
caused by cuprizone (CPZ) (Matsushima and Morell, 2001; Yang 
et al., 2009), a copper chelator. In the ﬁ  rst study by our lab, C57BL/6 
mice given CPZ showed schizophrenia-like behaviors including 
deﬁ  cits in prepulse inhibition (PPI) of acoustic startle reﬂ  ex, less 
social interaction, and impaired spatial working memory. These 
animals also showed evident myelin sheath loss and decrease in the 
number of OLs in the brain (Xu et al., 2009). In the second study 
adolescent rats exposed to CPZ showed decreased expression of 
mRNA transcripts encoding oligodendroglial proteins within the 
medial prefrontal cortex (PFC); these rats also displayed a speciﬁ  c 
deﬁ  cit in the ability to shift between perceptual dimensions in the 
attention set-shifting task (Gregg et al., 2009), a PFC-mediated 
behavioral paradigm modeled after the Wisconsin Card Sorting Test 
(Franke et al., 1992). These studies suggest that the CPZ-exposed 
mice/rats are potential animal models of schizophrenia to test the 
OL hypothesis.
For the ﬁ  rst time, this study examined effects of some antip-
sychotics on the behavioral abnormalities and neurobiological 
changes seen in C57BL/6 mice exposed to cuprizone. Our results 
provided experimental evidence supporting a role for altered OLs 
in the pathophysiology and treatment of schizophrenia. The drugs 
INTRODUCTION
Schizophrenia is one of the most severe psychiatric disorders, affect-
ing about 1% of the worldwide population. The symptoms of the 
disorder are usually classiﬁ  ed as positive, negative, and cognitive 
symptoms (Carpenter and Buchanan, 1994). Positive symptoms 
include hallucinations, delusions, and thought disorganization. 
Negative symptoms are a group of deﬁ  cits comprising many dimen-
sions, such as diminished emotional response, social withdrawal, 
blunted affect, poverty of speech, and lack of energy. Cognitive 
symptoms include deﬁ  cits in attention, executive function, and 
memory. Patients usually come to clinical attention because of their 
positive symptoms.
Although the etiology and fundamental pathophysiology of 
schizophrenia remain unclear, signiﬁ  cant advances have been made 
in recent human studies. First, neuroimaging studies have shown 
white matter abnormalities and enlarged ventricles in schizophrenic 
brains (Ardekani et al., 2003; Davis et al., 2003; Kubicki et al., 2005). 
Second, genome-wide expression analyses have shown dysregula-
tion of genes related to oligodendrocyte (OL) function and myeli-
nation in schizophrenia (Hakak et al., 2001; McCullumsmith et al., 
2007). Third, patients with white matter disorders experience a 
host of psychotic symptoms (Kohler et al., 1988; Hyde et al., 1992; 
Bassett et al., 2003). These previous studies suggest a putative role 
for altered OLs in the pathophysiology of schizophrenia. However, 
experimental evidence for this novel hypothesis has been scarce.
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tested are haloperidol (HAL), clozapine (CLZ), and quetiapine 
(QUE). HAL is a prototype of the ﬁ  rst-generation antipsychotics, 
while CLZ and QUE are second-generation antipsychotics (SGAs). 
These drugs are being used for patients with schizophrenia, but 
have different therapeutic actions and mechanisms. HAL is effec-
tive in reducing psychotic symptoms, but has poor effects on the 
negative and cognitive symptoms (Ellenbroek, 1993), while CLZ 
and QUE are effective in improving negative symptoms and cogni-
tive deﬁ  cits (Kane et al., 1988; Harvey and Keefe, 2001; Woodward 
et al., 2005). HAL has a high afﬁ  nity for D2 receptors (Seeman, 
2006) whereas CLZ and QUE are broad-acting agents, which not 
only exhibit afﬁ  nity for a variety of DA receptors, but also for other 
metabotropic receptors, e.g. those for serotonin (5-HT2A and 
5-HT1), norepinephrine (NE), acetylcholine and histamine 
(Meltzer, 1995; Seeman, 2002; Reynolds, 2004). Blocking D2 recep-
tors in mesolimbic areas is believed to be responsible for the thera-
peutic effects on the positive symptoms (Seeman, 2006). However, 
the mechanisms underlying the improvement of negative and cog-
nitive symptoms by SGAs remain to be elucidated.
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
CPZ, HAL, and CLZ were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). QUE was provided by AstraZeneca Canada (Mississauga, 
Ontario). CPZ was mixed into a standard powdered rodent chow 
at the ﬁ  nal concentration 0.2% (w/w). All the antipsychotics were 
freshly prepared (dissolved in 0.8% glacial acetic acid in saline and 
pH value was adjusted to 6.8) and administered intraperitoneally 
(i.p; 1 ml/100 g body weight) once a day. On the behavioral test day, 
antipsychotics were administered after ﬁ  nishing behavioral tests. 
Based on previous studies (Xu et al., 2002; Bai et al., 2003, 2004) 
1 mg/kg/day of HAL, 10 mg/kg/day of CLZ and QUE were used in 
this study. The primary antibody to MBP and secondary antibody 
were purchased from Millipore (Temecula, CA, USA), antibody 
to β-actin from Sigma-Aldrich, the ABC kits from Vector Labs 
(Burlingame, CA, USA), and the ECL plusTM kit from Amersham 
Biosciences (Buckinghamshire, UK).
EXPERIMENTAL DESIGN
Male C57BL/6 mice (6-weeks old, 20 to 22 g) were purchased 
from Charles River Laboratories (Wilmington, MA, USA). After 
an acclimatization period of 10 days, the C57BL/6 mice were given 
0.2% by weight CPZ in the standard powdered rodent chow for 
14–42 days, during which age-matched mice received the stand-
ard chow without CPZ and were used as controls. Three inde-
pendent experiments were performed for HAL, CLZ, and QUE, 
respectively. Each experiment consisted of four animal groups 
designed to examine effects of CPZ on animals’ behaviors and 
white matter and effects of the antipsychotics in mice without or 
with CPZ-exposure. For example, HAL experiment included CNT, 
CPZ, HAL, and CPZ+HAL groups. CNT group mice ate normal 
rodent chow without CPZ and received no HAL; CPZ group mice 
ate CPZ-containing rodent chow and received no HAL; HAL group 
mice ate normal rodent chow without CPZ but received HAL 
treatment (1 mg/kg/day, i.p.); CPZ + HAL group mice ate CPZ-
containing rodent chow and received HAL treatment. The experi-
mental period was 42 days, during which mice were   subjected to 
  behavioral tests at indicated time points. For   high-performance 
liquid   chromatography (HPLC) analysis, two additional experi-
ments were performed, in which the same treatments (CPZ 
ingestion and antipsychotics administration) continued for 12 
and 21 days, respectively. Each of the experiments consisted of 
eight animal groups (CNT, CPZ, HAL, CLZ, QUE, CPZ+HAL, 
CPZ+CLZ, and CPZ+QUE; 5–8 mice/group). All animal proce-
dures in this study were in accordance with the National Institute 
of Health Guide for the Care and Use of Laboratory Animals and 
were approved by the Animal Care and Use Committee of Southern 
Illinois University Carbondale.
PREPULSE INHIBITION TEST
PPI refers to the inhibition of a startle reﬂ  ex produced by preceding 
the startling stimulus, or pulse, with a weak prepulse stimulus. This 
test provides an operational measure of sensory gating of subjects. 
In our recent study, CPZ-exposed mice showed PPI deﬁ  cits on 14th 
and 21st days after CPZ-exposure (Xu et al., 2009). In this study PPI 
test was performed on 14th day after CPZ-exposure. As described 
in our recent study (Xu et al., 2009), each mouse was placed into a 
small Plexiglas cylinder within a large sound-attenuating chamber 
(San Diego Instruments, CA, USA). The cylinder was seated upon 
a piezoelectric transducer, which allows vibrations to be quanti-
ﬁ  ed and displayed on a computer. The background sound levels 
(74–75 dB) and calibration of the acoustic stimuli were conﬁ  rmed 
with a digital sound level meter. After a 5-min habituation period, 
PPI test sessions were conducted. Each session started and ended 
with ﬁ  ve startle trials (40 ms; 120 dB), respectively. Between the 
starting and ending startle trials, there were eight identical blocks 
consisting of the following ﬁ  ve trials: a no-stimulus trial, a startle 
trial, and three prepulse-startle trials, each of which had a pre-pulse 
stimulus (3, 6, or 12 dB above the background sound levels) prior to 
a startle stimulus (100 ms after the prepulse). The average inter-trial 
interval was 15 s. Measures were taken of the startle amplitude for 
each trial, deﬁ  ned as the peak response during a 65-ms sampling 
window starting from the onset of a startle stimulus. Levels of PPI 
at each prepulse sound level were calculated as 100 × (1-averaged 
response amplitude in trials with a prepulse stimulus and startle 
stimulus/averaged response amplitude in trials with the startle 
stimulus alone).
Y-MAZE TEST
The Y-maze is a simple two-trial recognition test for measuring spa-
tial recognition memory. In a previous study (Oades et al., 1985), 
amphetamine reduced alternation dose-dependently and HAL 
pretreatment inhibited this effect, suggesting that this paradigm 
is useful for studying spatial working memory in animal models 
of schizophrenia. In our recent study, CPZ-exposed mice showed 
lower spontaneous alternation in Y-maze on 14th, 21st, 28th, 35th, 
and 42nd days after CPZ-exposure (Xu et al., 2009). In this study Y-
maze test was performed on 21st and 42nd days after CPZ-exposure. 
As described in our recent study (Xu et al., 2009), each mouse was 
placed at the end of one arm of a symmetrical Y-maze and allowed 
to move freely through the maze during an 8-min test period. The 
total number and series of arm entries were recorded. The number 
of overlapping entrance sequences (e.g., ABC, BCA) deﬁ  nes the 
number of spontaneous alternations.Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 3
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SOCIAL INTERACTION TEST
In our recent study, CPZ-exposed mice showed less social interac-
tion on 28th, 35th, and 42nd days after CPZ-exposure (Xu et al., 
2009). In this study social interaction test was performed on 28th 
day after CPZ-exposure. As described in our recent study (Xu et al., 
2009), pairs of unfamiliar mice (that had been housed separately) of 
the same experimental group were placed in the center of an open-
ﬁ  eld box (56 cm × 56 cm × 31 cm) about 10 cm apart. A video cam-
era was placed above the open-ﬁ  eld box to monitor the animals’ 
movement. During a 10 min test period, the social interaction of 
the animals was deﬁ  ned when the tested mice were closer than 5 cm 
(between the center point of the back of a mouse and another one) 
for at least 0.2 s. Each mouse was used only one time. The results 
were recorded and analyzed automatically by the video tracking 
program SMART, which counted the amount of time spent near 
another mouse for two mice simultaneously. Although this method 
only measures closeness of subjects examined, it has been used in 
previous studies and the closeness is believed to reﬂ  ect social inter-
actions (Shi et al., 2003; Egashira et al., 2007), which is an animal 
correlate of social withdrawal seen in patients with schizophrenia 
(Weinberger, 1987; Abi-Dargham et al., 2000). Social behavioral 
deﬁ  cit has been reported in various animal models of schizophrenia 
(Shi et al., 2003; Boucher et al., 2007; Lazar et al., 2008).
IMMUNOHISTOCHEMISTRY AND IMAGE ANALYSIS
For immunohistochemical staining, animals were deeply anesthe-
tized with chloral hydrate (400 mg/kg ip) and perfused through 
the ascending aorta with 0.1 M phosphate buffered saline (PBS; 
pH 7.4), followed by 4% paraformaldehyde in PBS. Their brains 
were then removed and immersed in the same ﬁ  xative overnight, 
followed by cryo-protection in 25% sucrose at 4°C for 24–48 h. 
Serial coronal sections (25 µm) of the brains were cut using a slid-
ing microtome (Lipshaw, Detroit, MI, USA) and collected in six 
well plates containing 0.01-M PBS. One set of the sections was 
used to assess the MBP-like immunoreactivity using the protocol 
as described previously (Yang et al., 2009). For quantitative analysis, 
ﬁ  ve sections from each brain region (CP and hippocampus) of 
each animal were digitally recorded using a DMI-4000B micro-
scope (Leica, Germany) equipped with a digital capture system. 
The optical densities of MBP-like immunoreactivity and positive 
stained area in the target regions were measured using the Image-
Pro Plus software (Version 6.0, Media Cybernetics, Inc., Bethesda, 
MD, USA) under the same conditions. In a same experiment, the 
value of the positive stained area in the target regions of CNT 
group was used as the standard for the normalization of the values 
of other groups.
WESTERN-BLOT ANALYSIS
Under deep anesthesia mice were sacriﬁ  ced, their brains were rap-
idly removed, and speciﬁ  c brain regions (PFC, CP, and hippocam-
pus) were dissected out and stored at -80°C until use. Western-blot 
was performed to assess the amount of MBP in each brain region 
using the antibody to MBP as described previously (Zhang et al., 
2008). Immunoreactive bands were visualized using a UVP Biodoc-
itTM system (UVP, Inc., Upload, CA, USA) and measured with the 
Image J software (NIH, Bethesda, MD, USA). The product of optical 
density and area of each band was calculated. For each lane, there is 
a ratio of MBP product/β-actin product. In a same experiment, the 
ratio of CNT group was used as the standard for the normalization 
of the ratios of other groups.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
In our recent study, CPZ-exposed mice showed changes in DA and 
NE on 14th and 21st days after CPZ-exposure, respectively (Xu 
et al., 2009). Therefore, the same time points were chosen for the 
measurement of these two neurotransmitters. Mice were decapi-
tated and the PFC was dissected out of the brain and frozen at -80°C 
until use. DA and NA levels in PFC of mice were measured using 
HPLC method as described in our recent study (Xu et al., 2009).
DATA ANALYSIS
Quantitative data were analyzed by two-way analysis of variance 
considering CPZ treatment and antipsychotic administration 
as two main factors, followed by Tukey’s multiple comparisons. 
When a p-value was less than 0.05, the difference/effect was 
considered signiﬁ  cant.
RESULTS
ANTIPSYCHOTICS BLOCK THE DEFICIT OF CPZ-EXPOSED MICE IN THE 
PREPULSE INHIBITION
In the HAL experiment (Figure 1A), when the prepulse of 3 db 
was applied, no signiﬁ  cant effect was found by two-way ANOVA 
[F(3, 39) = 0.77; p = 0.5]. And no differences were found between 
any two groups. When the prepulse of 6 db was applied, two-way 
ANOVA (F(3, 39) = 4.27; p = 0.024) revealed a signiﬁ  cant interac-
tion between the two main factors (CPZ and HAL treatments). 
And signiﬁ  cant differences were also found in the comparisons 
of CNT and CPZ, CNT and HAL, as well as CPZ and CPZ+HAL 
(individual F and p values were not presented). When the prepulse 
of 12 db was applied, two-way ANOVA (F(3, 39) = 4.07; p = 0.017) 
revealed a signiﬁ  cant interaction between the two main factors. 
And signiﬁ  cant differences were also found in the comparisons of 
CNT and CPZ, as well as CPZ and CPZ+HAL (individual F and p 
values were not presented). Similar results were also found in CLZ 
(Figure 1B) and QUE (Figure 1C) experiments. But unlike HAL, 
CLZ and QUE did not caused a PPI deﬁ  cit.
DIFFERENT EFFECTS OF ANTIPSYCHOTICS ON THE ABNORMAL 
PERFORMANCE OF CPZ-EXPOSED MICE IN Y-MAZE
In the HAL experiment (Figures 2A,B), CPZ-exposure for 21 days 
lowered (p = 0.001) the spontaneous alternation in Y-maze test. 
But no differences were found between other groups. HAL alone 
decreased the number of arm entries compared to CNT, suggest-
ing a sedative effect of this drug on the mice. When CPZ-exposure 
was extended for 42 days, a more signiﬁ  cant (p = 0.0002) lower 
spontaneous alternation was found. Moreover, lower spontane-
ous alternations were also found in HAL and CPZ + HAL groups, 
suggesting that HAL alone had an adverse effect on this behavioral 
performance and that this drug was unable to prevent mice from 
the effect of CPZ on this performance. And the sedative effect was 
found in HAL and CPZ + HAL groups. In the CLZ experiment 
(Figures 2C,D), CPZ-exposure for 21 days lowered the spontane-
ous alternation (p = 0.011). And lower spontaneous alternation 
was also found in the CPZ + CLZ group but was not signiﬁ  cant Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 4
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FIGURE 1 | Effects of antipsychotics on the CPZ-induced deﬁ  cits in PPI test. 
Control and experimentally treated C57BL/6 mice were subjected to PPI test on 
the same day (14th day after CPZ-exposure). (A) The data of the HAL experiment. 
(B) The data of the CLZ experiment. (C) The data of the QUE experiment. Data 
were expressed as M ± SEM (n = 6 to 12/group). CNT, Control group; CPZ, 
Cuprizone group; CLZ, Clozapine group; HAL, Haloperidol group; QUE, Quetiapine 
group; CPZ + CLZ, mice received both cuprizone and clozapine; CPZ + HAL, mice 
received both cuprizone and haloperidol; CPZ + QUE, mice received both 
cuprizone and quetiapine. PPI = Prepulse inhibition; db = Decibel. *p < 0.05, 
**p < 0.01, compared to the CNT group; +p < 0.05, compared to the CPZ group.
FIGURE 2 | Effects of antipsychotics on the CPZ-induced abnormal 
performance in the Y-maze test. Control and experimentally treated C57BL/6 
mice were subjected to Y-maze test on the same days (21st and 42nd days after 
CPZ-exposure). (A) The data of the spontaneous alternation in the HAL experiment. 
(B) The data of the number of arm entries in the HAL experiment. (C) The data of 
the spontaneous alternation in the CLZ experiment. (D) The data of the number of 
arm entries in the CLZ experiment. (E) The data of the spontaneous alternation in 
the QUE experiment. (F) The data of the number of arm entries in the QUE 
experiment. Data were expressed as M ± SEM (n = 6 to 12/group). *p < 0.05, 
**p < 0.01, compared to the CNT group; ++p < 0.01, compared to the CPZ group.Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 5
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(p = 0.064). Interestingly, mice exposed to CPZ for 21 days showed 
more number of arm entry in this experiment. But, this increase 
was not found in the CPZ + CLZ group. When CPZ-exposure was 
extended for 42 days, the CPZ-induced lower spontaneous alter-
nation was not found in the CPZ + CLZ group. Moreover, mice 
exposed to CLZ for 42 days had fewer number of arm entries 
(p = 0.02). In the QUE experiment (Figures 2E,F), CPZ-induced 
lower spontaneous alternation was not found in the CPZ + QUE 
group (Figure 2E); but, the treatments did not affect the number 
of arm entries in QUE and CPZ + QUE groups (Figure 2F).
CLZ AND QUE, BUT NOT HAL, BLOCK THE ABNORMAL PERFORMANCE OF 
CPZ-EXPOSED MICE IN SOCIAL INTERACTION
In the ﬁ  rst 20–30 s, the tested mice moved about but avoided the 
partner in the open ﬁ  eld. Then, avoiding behaviors disappeared and 
social interactions became frequent, including snifﬁ  ng the partner’s 
body, grooming the partner, and mounting the partner. In the HAL 
experiment (Figure 3A), two-way ANOVA revealed a signiﬁ  cant 
interaction between CZP and HAL treatments [F  (3, 23) = 16.59, 
p < 0.001]. Post hoc comparisons found signiﬁ  cant differences 
between CNT and other groups (CPZ, HAL, and CPZ+HAL), 
but not between any other two groups. In the CLZ experiment 
(Figure 3B), two-way ANOVA revealed a signiﬁ  cant interaction 
between CZP and CLZ treatments [F(3, 23) = 5.98, p < 0.01]. Post 
hoc comparisons found a signiﬁ  cant difference between CNT and 
CPZ groups. The difference between CPZ and CPZ + CLZ groups 
was also signiﬁ  cant. But, no differences were found between any 
other two groups. In the QUE experiment (Figure 3C), two-way 
ANOVA revealed a signiﬁ  cant interaction between CZP and QUE 
treatments [F(3, 23) = 3.85, p < 0.05]. Post hoc comparisons found a 
signiﬁ  cant difference between CNT and CPZ groups. But, no dif-
ferences were found between any other two groups.
ANTIPSYCHOTICS BLOCK THE CHANGED LEVELS OF DA AND NE IN PFC 
OF CPZ-EXPOSED MICE
In the measurement of DA levels in PFC (Figure 4A), no signiﬁ  cant 
effect was revealed by one-way ANOVA [F(7, 64) = 1.1, p > 0.05]. Post 
hoc comparisons found a signiﬁ  cant difference between CNT and 
CPZ groups (p =  0.032). But, no differences were found between 
any other two groups. HAL and CLZ, but not QUE, seemed to 
increase DA levels in mice that consumed normal diet without 
CPZ, although this effect did not reach the pre-set signiﬁ  cant level. 
In the measurement of NE (Figure 4B), no signiﬁ  cant effect was 
revealed by one-way ANOVA [F(7, 83) = 2.02, p > 0.05]. Post hoc 
comparisons found a signiﬁ  cant difference between CNT and CPZ 
groups (p = 0.025). But, no differences were found between any 
other two groups.
CLZ AND HAL BLOCK THE DECREASE IN THE AMOUNT OF MBP IN PFC OF 
CPZ-EXPOSED MICE
In our recent studies (Xiao et al., 2008; Zhang et al., 2008), QUE 
showed protective effects on the CPZ-induced myelin sheath loss and 
decrease in the amount of MBP in the cerebral cortex of C57BL/6 
mice. In this study, we sought to determine if HAL and CLZ have 
FIGURE 3 | Effects of antipsychotics on the CPZ-induced deﬁ  cits in the social 
interaction. Control and experimentally treated C57BL/6 mice were subjected to 
social interaction test on the same day (28th day after CPZ-exposure). (A) The data 
of the HAL experiment. (B) The data of the CLZ experiment. (C) The data of the 
QUE experiment. Data were expressed as M ± SEM (n = 6 pairs/group). *p < 0.05, 
**p < 0.01, compared to the CNT group; +p < 0.05, compared to the CPZ group.
FIGURE 4 | Effects of antipsychotics on the CPZ-induced changes in levels 
of DA and NE in PFC. (A) Control and experimentally treated C57BL/6 mice 
were sacriﬁ  ced on 14th day after CPZ-exposure. DA levels in PFC were 
measured by means of HPLC. (B) Control and experimentally treated 
C57BL/6 mice were sacriﬁ  ced on 21st day after CPZ-exposure. NE levels 
in PFC were measured by means of HPLC. Data were expressed as 
M ± SEM (ng/g tissue; n = 6 to 12/group). *p < 0.05, compared to the 
CNT group.Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 6
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FIGURE 5 | Effects of HAL and CLZ on the CPZ-induced decrease in MBP 
in PFC. Control and experimentally treated C57BL/6 mice were sacriﬁ  ced on 
43rd day after CPZ-exposure. The PFC was dissected out of the brain and 
processed for Western-blot analysis to measure MBP levels. The upper 
photographs (A) and (B) are representative Western-blots from HAL and CLZ 
experiments, respectively. The bar charts (C) and (D) in the bottom panel are 
the statistical results of the amount of MBP relative to β-actin in the same 
corresponding lanes as labeled. Data were expressed as M ± SEM (n = 6/
group). *p < 0.05, **p < 0.01, compared to the CNT group. +p < 0.05, 
compared to the CPZ group.
similar protective effects. CPZ-exposure for 42 days dramatically 
decreased the amount of MBP in PFC. But, this decrease was amel-
iorated in mice that exposed to CPZ and HAL/CLZ although those 
treated with the antipsychotics alone showed similar MBP immuno-
reactive bands to that of CNT (Figures 5A,B). The results of statisti-
cal analysis against the quantitative data were shown in the bottom 
panel of Figures 5C,D. For the HAL experiment (Figure 5C), two-
way ANOVA revealed a signiﬁ  cant interaction between CPZ and 
HAL treatments [F(3, 19) = 18.61, p < 0.001]. Post hoc comparisons 
revealed signiﬁ  cant differences between CNT and CPZ groups as well 
as between CNT and CPZ + HAL groups. The difference between 
CPZ and CPZ + HAL was also signiﬁ  cant. For the CLZ experiment 
(Figure 5D), two-way ANOVA revealed a signiﬁ  cant interaction 
between CPZ and CLZ treatments [F(3, 19) = 10.74, p < 0.001]. Post 
hoc comparisons revealed signiﬁ  cant differences between CNT and 
CPZ groups as well as between CNT and CPZ+CLZ groups. The 
difference between CPZ and CPZ+CLZ was also signiﬁ  cant.
CLZ AND QUE, BUT NOT HAL, PROTECT THE WHITE MATTER IN CP OF 
CPZ-EXPOSED MICE
In our recent study (Yang et al., 2009), CPZ-exposed mice showed 
obvious myelin sheath loss in the ventral and lateral parts of CP, 
where smaller ﬁ  ber tracts are located. In this study, we sought to 
examine effects of antipsychotics on the CPZ-induced white mat-
ter damage. Similar to our recent study, myelin sheath loss was 
seen in CP of CPZ-exposed mice and this CPZ-induced white 
matter damage was ameliorated by CLZ and QUE, but not HAL 
(Figures 6A–C). Quantitative measurement and comparisons 
conﬁ   rmed the morphological observations (Figures 6D–F). 
These results suggest that CLZ and QUE, but not HAL, protect 
the white matter in CP of mice exposed to CPZ. To further con-
ﬁ  rm these effects, Western-blot analysis was performed to measure 
the amount of MBP in CP. Signiﬁ  cant decreases in the amount of 
MBP in CP were seen in all experiments (Figure 7). In the HAL 
experiment (Figures 7A,D), this decrease in the amount of MBP 
was not affected by HAL as the CPZ + HAL group showed a com-
parable amount of MBP to that of the CPZ group. In the CLZ 
experiment (Figures 7B,E), this decrease in the amount of MBP was 
signiﬁ  cantly ameliorated by CLZ as the CPZ + CLZ group showed 
a higher level of MBP compared to the CPZ group. QUE showed 
a similar protective effect (Figures 7C,F) as CLZ did. In addition, 
we did similar analyses (immunohistochemistry and Western-blot) 
against the  hippocampus and obtained the similar results support-
ing the protective effects of CLZ and QUE on the CPZ-induced 
white matter damage (not shown).
DISCUSSION
Although many animal models of schizophrenia have been devel-
oped, no one could mimic the neuropathological feature of white 
matter abnormalities in schizophrenic brains. For the ﬁ  rst time, a 
new animal model has been established in this study which shows 
white matter alterations in PFC, CP and the hippocampus, in 
addition to the abnormal behaviors mimicking the heterogene-
ity of schizophrenia symptoms. These behavioral changes include 
PPI deﬁ  cits (Figure 1), a lower spontaneous alternation in the 
Y-maze (Figure 2), and less time in social interaction (Figure 3). 
Furthermore, HAL and SGAs showed different effects on the CPZ-
induced behavioral and neurobiological changes, which remind us 
of the different therapeutic effects of these antipsychotics in treating 
patients with schizophrenia.
CPZ-treated mice showed PPI deﬁ  cits while they had higher 
levels of DA in their PFC, suggesting an association between these 
two variables. In support of the existence of this association, DA 
levels in CPZ-treated mice returned to CNT levels when PPI 
 deﬁ  cits disappeared (Xu et al., 2009). Furthermore, all antipsy-
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FIGURE 6 | CLZ and QUE, but not HAL, protect the CPZ-induced myelin 
sheath loss in CP . (A) Images showing MBP-like immunoreactivity (MBP-LI) in 
CP of mice in the HAL experiment. (B) Images showing MBP-LI in CP of mice in 
the CLZ experiment. (C) Images showing MBP-LI immunoreactivity in CP of 
mice in the QUE experiment. (D) The bar chart of MBP-LI area in tissue sections 
of CP in the HAL experiment. (E) The bar chart of MBP-LI area in tissue sections 
of CP in the CLZ experiment. (F) The bar chart of MBP-LI area in tissue sections 
of CP in the QUE experiment. Data were expressed as M ± SEM (n = 6/group). 
*p < 0.05, **p < 0.01, compared to the CNT group. +p < 0.05, ++p < 0.01, 
compared to the CPZ group.
FIGURE 7 | Effects of antipsychotics on the CPZ-induced decrease in MBP 
in CP . Control and experimentally treated C57BL/6 mice were sacriﬁ  ced on 
43rd day after CPZ-exposure. The CP was dissected out of the brain and 
processed for Western-blot analysis to measure MBP levels. The upper 
photographs (A–C) are representative Western-blots from the HAL, CLZ, and 
QUE experiments, respectively. The bar charts (D–F) in the bottom panel are 
the statistical results of the amount of MBP relative to β-actin in the same 
corresponding lanes as labeled. Data were expressed as M ± SEM (n = 6/
group). **p < 0.01, compared to the CNT group; ++p < 0.01, compared to the 
CPZ group.
PPI deﬁ  cits (Figure 1) and attenuated the CPZ-induced high levels 
of DA in PFC (Figure 4). These are in accordance with previous 
studies showing that antipsychotic agents reverse drug-induced 
deﬁ  cits in animal models of sensorimotor gating (Olivier et al., 
2001; Ouagazzal et al., 2001). Together, all these data suggest that the 
gating deﬁ  cits in schizophrenia result from increased dopaminergic 
neurotransmission in the brain, a proposal supported by a previous 
study that implicates forebrain DA over-activity in the etiology of 
reduced PPI (Swerdlow et al., 1986). However, it should be noted 
that, the antipsychotics alone did not decrease DA levels in PFC. 
Instead, HAL and CLZ seemed to increase DA levels. Therefore, 
it may be interpreted that antipsychotics improved PPI deﬁ  cits Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 8
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mainly by blocking DA receptors (D2 receptors, most likely). This 
interpretation is in line with the evidence that the administration 
of DA agonists can disrupt PPI in humans (Hutchison and Swift, 
1999; Swerdlow et al., 2003) and in animals (Mansbach et al., 1988; 
Swerdlow et al., 1990).
In a previous study, amphetamine reduced spontaneous alterna-
tion dose-dependently and HAL pretreatment inhibited this effect 
(Oades et al., 1985), suggesting the involvement of central DA activ-
ity in the performance of mice in Y-maze test. In our recent study 
(Xu et al., 2009), a lower spontaneous alternation in the Y-maze was 
found in CPZ-treated mice starting from 14th day after CPZ treat-
ment when DA levels increased in PFC and remained throughout 
the whole 6-weeks experimental period. In the present study, HAL 
treatment for 21 days attenuated the CPZ-induced lower spontane-
ous alternation; but when the same HAL treatment continued for 
42 days this attenuating effect disappeared. Moreover, HAL alone 
(for 42 days) caused a lower spontaneous alternation in control 
mice (Figure 2A). Together, all these results provide further evi-
dence for the involvement of DA in the performance of mice in 
Y-maze test. In addition, the observation of the present study that 
HAL treatment for 21 days, but not for 42 days, attenuated the 
CPZ-induced decrease in spontaneous alternation may be related 
to a possible D2 receptor up-regulation achieved by chronic (for 
42 days) administration of HAL. The D2 receptor upregulation 
caused by chronic antipsychotic exposure was described in both 
animals (Burt et al., 1977; Ginovart et al., 2009) and patients with 
schizophrenia (Lee et al., 1978; Mackay et al., 1982) and now is 
thought to be responsible for loss of efﬁ  cacy of antipsychotics. CLZ 
and QUE completely blocked the CPZ-induced lower spontaneous 
alternation in the Y-maze (Figure 2) and did not show the loss of 
efﬁ  cacy as HAL did. This is consistent with their lower afﬁ  nities 
for D2 receptors (Kasper et al., 1999).
The CPZ-treated mice did not show deﬁ  cit in social interaction 
until 4th week after CPZ-exposure when the loss of myelin sheath 
and MBP became evident (Xu et al., 2009), suggesting normal 
performance in social interaction relies on intact white matter. In 
support of this notion, low sociability is associated with reduced 
size of the corpus callosum in the mouse (Fairless et al., 2008). 
Although it is now unclear how white matter damage impairs the 
social interaction in CPZ-treated mice, some clues may be drawn 
from the following ﬁ  ndings of the present study: ﬁ  rst, HAL did 
not improve the performance of CPZ-treated mice in social inter-
action test (Figure 3A) whereas it mitigated the CPZ-induced 
MBP decrease in PFC (Figure 5); second, the myelin sheath loss 
in CPZ + CLZ and CPZ + QUE groups were still obvious (Figure 6) 
but their performance in social interaction test was comparable to 
that of the CNT group (Figure 3). These results suggest a reasonable 
interpretation that the improvement of the performance of CPZ-
treated mice in the social interaction by CLZ and QUE is mainly 
due to the actions of these two drugs on various neurotransmit-
ter systems that had become dysfunctional following white matter 
damage. HAL acts on D2 receptors mainly while CLZ and QUE 
are broad-acting agents with afﬁ  nities for receptors of a variety of 
neurotransmitters; therefore, HAL did not have the same beneﬁ  -
cial effects on the social interaction deﬁ  cit as CLZ and QUE did. 
In line with this interpretation, a recent study (Roy et al., 2007) 
reported increased levels of DA receptors in the transgenic mice 
with OL alterations. In future studies, we will address which and 
how neurotransmitter systems become dysfunctional following 
white matter damage.
Consistent with previous studies (Prohaska and Bailey, 1993; Xu 
et al., 2009), CPZ-treated mice had lower NE levels in PFC while 
they showed abnormal behaviors, suggesting the involvement of NE 
system in the CPZ-induced abnormal behaviors. The decrease in 
NE levels may be related to the inhibition of the activity of DA β-
hydroxylase (DβH), a cupric enzyme which catalyzes the synthesis of 
NE from DA. In fact, C57BL/6 mice fed the CPZ-containing diet for 
21 days showed lower activity of DβH in the hippocampus and PFC 
as compared to normal controls (Xu et al., 2009). More interestingly, 
the CPZ-induced decrease in NE levels was blocked by the antipsy-
chotics tested in this study (Figure 4). These results are in line with 
the following previous ﬁ  ndings: antipsychotics including HAL and 
SGAs dose dependently increase NE release in the rat medial PFC 
and hippocampus (Westerink et al., 1998); systemic administration 
of HAL and CLZ increases the ﬁ  ring rate of NE neurons in locus 
coeruleus (Nilsson et al., 2005), the primary source of the noradren-
ergic innervations of the forebrain; and QUE increases levels of NE 
in both PFC and the caudate nucleus (Pira et al., 2004).
Both CLZ and HAL ameliorated the decrease in the amount 
of MBP in PFC of mice exposed to CPZ (Figure 5) and the same 
drugs also blocked the CPZ-induced high levels of DA in the 
same brain region (Figure 4). This association between normal-
ized DA levels and ameliorated MBP changes in PFC implies 
that high levels of DA may contribute to the CPZ-induced white 
matter damage in PFC. In support of this speculation, previous 
studies have shown that high levels of DA act as an endogenous 
neurotoxin (Bozzi and Borrelli, 2006) and may damage OLs by 
increasing free radical generation (Khorchid et al., 2002). The 
mitochondrial impairment and metabolic stress, in turn, increase 
DA efﬂ  ux (Moy et al., 2007). Therefore, it is reasonable to sug-
gest a mechanism that CLZ and HAL act on DA system (DA 
levels and/or DA receptors) in PFC thus protect the white mat-
ter there of CPZ-exposed mice. By this mechanism, these two 
drugs block the PPI deﬁ  cit and lower spontaneous alternation 
in CPZ-treated mice.
Both CLZ and QUE, but not HAL, protect the white matter in CP 
of mice exposed to CPZ (Figures 6 and 7), suggesting that additional 
mechanisms are involved in the protective effect of these two SGAs 
besides the anti-dopaminergic action shared by all the three antip-
sychotics as discussed above. Although this study did not address 
what are the exact mechanisms, our recent work on QUE allows us 
to suggest a most likely mechanism that QUE protects CPZ-induced 
white matter damage mainly by its antioxidative actions. Our recent 
ﬁ  ndings supporting the antioxidative actions of QUE include: (1) 
QUE scavenges hydroxyl radical produced in the Fenton reaction 
and in the Aβ25–35 solution (Xu et al., 2008); (2) QUE prevents 
PC12 cell death caused by increased intracellular reactive oxygen 
species and calcium (Wang et al., 2005); and (3) QUE attenuates the 
CPZ-induced decrease in the activity of SOD1 in the cerebral cortex 
of mice (Zhang et al., 2008). This suggested mechanism is also in 
accordance with the mechanism by which CPZ damages OLs. That is, 
CPZ decreases activities of cupric enzymes, such as SOD1 (Ljutakova 
and Russanov, 1985) and cytochrome oxidase (Wakabayashi et al., 
1978), thus causes oxidative stress and leads to OLs death and Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 9
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Khorchid, A., Fragoso, G., Shore, G., and 
Almazan, G. (2002). Catecholamine-
 demyelination in the brain (Mason et al., 2004; Copray et al., 2005). 
CLZ may possess a similar mechanism because this antipsychotic 
acts as a very good antioxidant in lipid peroxidation produced in 
microsomal membranes (Dalla Libera et al., 1998).
In summary, CPZ acts on cupric enzymes, including SOD1, 
cytochrome oxidase, and DβH thus causes oxidative stress and 
increases DA levels in certain brain regions such as PFC (Figure 4). 
High levels of DA results in abnormal behaviors such as PPI deﬁ  cits 
(Figure 1), and exacerbates the oxidative stress, which is fatal to 
OLs. The loss of myelin sheath integrity (Figure 6) not only affects 
the communication between different brain regions and may impair 
the coordination and balance of different neurotransmitter systems 
in the brain. As a result of these changes, CPZ-treated mice show 
more behavioral alterations including the social interaction deﬁ  -
cit and impairment in spatial working memory (Figures 2 and 3). 
HAL has high afﬁ  nities for D2 receptors, thus improves the CPZ-
induced PPI deﬁ  cit and impairment in spatial working memory. In 
addition to DA system, CLZ and QUE act on more neurotransmit-
ter systems thus improve more behavioral changes seen in CPZ-
treated mice. Moreover, these two SGAs have antioxidant properties 
thus protect mice against the CPZ-induced white matter damage 
(Figures 5,6 and 7). This protective action may also contribute to 
the drugs’ effects on the social interaction deﬁ  cit and impairment 
in spatial working memory in CPZ-treated mice.
ACKNOWLEDGMENTS
This study was supported by a start-up fund from the School of 
Medicine, Southern Illinois University Carbondale and a faculty 
seed fund from the University to Haiyun Xu. Drs Gregory Rose and 
Rich Clough read the manuscript.
REFERENCES
Abi-Dargham, A., Rodenhiser, J., Printz, 
D., Zea-Ponce, Y., Gil, R., Kegeles, L. 
S., Weiss, R., Cooper, T. B., Mann, J. 
J., Van Heertum, R. L., Gorman, J. M., 
and Laruelle, M. (2000). Increased 
baseline occupancy of D2 receptors by 
dopamine in schizophrenia. Proc. Natl. 
Acad. Sci. U.S.A. 97, 8104–8109.
Ardekani, B. A., Nierenberg, J., Hoptman, 
M. J., Javitt, D. C., and Lim, K. O. 
(2003). MRI study of white matter 
diffusion anisotropy in schizophrenia. 
Neuroreport 14, 2025–2029.
Bai, O., Chlan-Fourney, J., Bowen, R., 
Keegan, D., and Li, X. M. (2003). 
Expression of brain-derived neu-
rotrophic factor mRNA in rat hip-
pocampus after treatment with 
antipsychotic drugs. J. Neurosci. Res. 
71, 127–131.
Bai, O., Zhang, H., and Li, X. M. (2004). 
Antipsychotic drugs clozapine and 
olanzapine upregulate bcl-2 mRNA 
and protein in rat frontal cortex 
and hippocampus. Brain Res. 1010, 
81–86.
Bassett, A. S., Chow, E. W., AbdelMalik, 
P., Gheorghiu, M., Husted, J., and 
Weksberg, R. (2003). The schizo-
phrenia phenotype in 22q11 dele-
tion syndrome. Am. J. Psychiatry 160, 
1580–1586.
Boucher, A. A., Arnold, J. C., Duffy, L., 
Schoﬁ  eld, P. R., Micheau, J., and Karl, 
T. (2007). Heterozygous neuregulin 1 
mice are more sensitive to the behav-
ioural effects of Delta9-tetrahydrocan-
nabinol. Psychopharmacology (Berl.) 
192, 325–336.
Bozzi, Y., and Borrelli, E. (2006). Dopamine 
in neurotoxicity and neuroprotection: 
what do D2 receptors have to do with 
it? Trends Neurosci. 29, 167–177.
Burt, D. R., Creese, I., and Snyder, S. H. 
(1977). Antischizophrenic drugs: 
chronic treatment elevates dopamine 
receptors binding in brain. Science 196, 
326–328.
Carpenter, W. T., and Buchanan, R. W. 
(1994). Schizophrenia. N. Engl. J. Med. 
330, 681–690.
Copray, J. C., Küst, B. M., Mantingh-Otter, 
I., and Boddeke, H. W. (2005). p75NTR 
independent oligodendrocyte death in 
cuprizone-induced demyelination in 
C57BL/6 mice. Neuropathol. Appl. 
Neurobiol. 31, 600–609.
Dalla Libera, A., Scutari, G., Boscolo, 
R., Rigobello, M. P., and Bindoli, A. 
(1998). Antioxidant properties of 
clozapine and related neuroleptcs. 
Free Radic. Res. 29, 151–157.
Davis, K. L., Stewart, D. G., Friedman, J. 
I., Buchsbaum, M., Harvey, P. D., Hof, 
P. R., Buxbaum, J., and Haroutunian, 
V. (2003). White matter changes in 
schizophrenia. Arch. Gen. Psychiatry 
60, 443–456.
Egashira, N., Tanoue, A., Matsuda, T., 
Koushi, E., Harada, S., Takano, Y., 
Tsujimoto, G., Mishima, K., Iwasaki, 
K., and Fujiwara, M. (2007). Impaired 
social interaction and reduced  anxiety-
related behavior in vasopressin V1a 
receptor knockout mice. Behav. Brain 
Res. 178, 123–127.
Ellenbroek, B. A. (1993). Treatment of 
schizophrenia: a clinical and preclini-
cal evaluation of neuroleptic drugs. 
Pharmacol. Ther. 57, 1078.
Fairless, A. H., Dow, H. C., Toledo, M. M., 
Malkus, K. A., Edelmann, M., Li, H., 
Talbot, K., Arnold, S. E., Abel, T., and 
Brodkin, E. S. (2008). Low   sociability 
is associated with reduced size of 
the corpus callosum in the BALB/cJ 
inbred mouse strain. Brain Res. 1230, 
211–217.
Franke, P., Maier, W., Hain, C., and 
Klingler, T. (1992). Wisconsin Card 
Sorting Test: an indicator of vulner-
ability to schizophrenia? Schizophr. 
Res. 6, 243–249.
Ginovart, N., Wilson, A. A., Hussey, 
D., Houle, S., and Kapur, S. (2009). 
D2-receptor upregulation is 
dependent upon temporal course 
induced oligodendrocyte cell death in 
culture is developmentally regulated 
and involves free radical generation 
and differential activation of caspase-
3. Glia 40, 283–299.
Kohler, J., Heilmeyer, H., and Volk, B. 
(1988). Multiple sclerosis presenting 
as chronic atypical psychosis. J. Neurol. 
Neurosurg. Psychiatr. 51, 281–284.
Kubicki, M., McCarley, R. W., and Shenton, 
M. E. (2005). Evidence for white mat-
ter abnormalities in schizophrenia. 
Curr Opin Psychiatry 18, 121–134.
Lazar, N. L., Ragakumar, N., and Cain, 
D. P. (2008). Injections of NGF into 
neonatal frontal cortex decrease social 
interaction as adults: a rat model of 
schizophrenia. Schizophr. Bull. 34, 
127–136.
Lee, T., Seeman, P., Tourtellotte, W. W., 
Farley, I. J., and Hornykeiwicz, O. 
(1978). Binding of 3H-neuroleptics 
and 3H-apomorphine in schizo-
phrenic brains. Nature 274, 897–900.
Ljutakova, S. G., and Russanov, E. M. 
(1985). Differences in the in vivo 
effects of cuprizone on superoxide 
dismutase activity in rat liver cytosol 
and mitochondrial intermembrane 
space. Acta Physiol. Pharmacol. Bulg. 
11, 56–61.
Mackay, A. V., Iversen, L. L., Rossor, M., 
Spokes, E., Bird, E., Arregui, A., Creese, 
I., and Synder, S. H. (1982). Increased 
brain dopamine and dopamine recep-
tors in schizophrenia. Arch. Gen. 
Psychiatry 39, 991–997.
Mansbach, R. S., Geyer, M. A., and Braff, 
D. I. (1988). Dopaminergic stimula-
tion disrupts sensorimotor gating in 
the rat. Psychopharmacology (Berl.) 
94, 507–514.
Mason, J. L., Toews, A., Hostettler, J. D., 
Morell, P., Suzuki, K., Goldman, J. 
E., and Matsushima, G. K. (2004). 
Oligodendrocytes and progenitors 
become progressively depleted within 
chronically demyelinated lesions. Am. 
J. Pathol. 164, 1673–1682.Frontiers in Behavioral Neuroscience  www.frontiersin.org  March  2010 | Volume  4 | Article  8 | 10
Xu et al.  A new schizophrenia model
Matsushima, G. K., and Morell, P. (2001). 
The neurotoxicant, cuprizone, as a 
model to study demyelination and 
remyelination in the central nervous 
system. Brain Pathol. 11, 107–116.
McCullumsmith, R. E., Gupta, D., Beneyto, 
M., Kreger, E., Haroutunian, V., Davis, 
K. L., and Meador-Woodruff, J. H. 
(2007). Expression of transcripts for 
myelination related genes in the ante-
rior cingulate cortex in schizophrenia. 
Schizophr. Res. 90, 15–27.
Meltzer, H. Y. (1995). Role of serotonin 
in the action of atypical antipsychotic 
drugs. Clin. Neurosci. 3, 64–75.
Moy, L. Y., Wang, S. P., and Sonsalla, P. K. 
(2007). Mitochondrial stress-induced 
dopamine efﬂ  ux and neuronal damage 
by malonate involves the dopamine 
transporter. J. Pharmacol. Exp. Ther. 
320, 747–756.
Nilsson, L. K., Schwieler, L., Engberg, G., 
Linderholm, K. R., and Erhardt, S. 
(2005). Activation of noradrenergic 
locus coeruleus neurons by cloza-
pine and haloperidol: involvement 
of glutamatergic mechanisms. Int. J. 
Neuropsychopharmacol. 8, 329–339.
Oades, R., Taghzouti, K., Simon, H., and Le 
Moal, M. (1985). Dopamine- sensitive 
alternation and collateral behavior in 
a Y-maze: effects of d-amphetamine 
and haloperidol. Psychopharmacology 
(Berl.) 85, 123–128.
Olivier, B., Leahy, C., Mullen, T., Paylor, 
R., Groppi, V. E., Sarnyai, Z., and 
Brunner, D. (2001). The DBA/2J strain 
and prepulse inhibition of startle: a 
model system to test antipsychot-
ics. Psychopharmacology (Berl.) 156, 
284–290.
Ouagazzal, A. M., Jenck, F., and 
Moreau, J. L. (2001). Drug-induced 
  potentiation of prepulse inhibition 
of acoustic startle reﬂ  ex in mice: a 
model for detecting antipsychotic 
activity? Psychopharmacology 156, 
273–283.
Pira, L., Mongeau, R., and Pani, L. (2004). 
The atypical antipsychotic quetiapine 
increases both noradrenaline and 
dopamine release in the rat prefrontal 
cortex. Eur. J. Pharmacol. 504, 61–64.
Prohaska, J. R., and Bailey, W. R. (1993). 
Persistent regional changes in brain 
copper, cuproenzymes and catecho-
lamines following perinatal copper 
deficiency in mice. J. Nutr. 123, 
1226–1234.
Reynolds, G. P. (2004). Receptor mecha-
nisms in the treatment of schizophre-
nia. J. Psychopharmacol. (Oxford) 18, 
340–345.
Roy, K., Murtie, J. C., El-Khodor, B. F., 
Edgar, N., Sardi, S. P., Hooks, B. M., 
Benoit-Marand, M., Chen, C., Moore, 
H., O’Donnell, P., Brunner, D., and 
Corfas, G. (2007). Loss of erbB sign-
aling in oligodendrocytes alters myelin 
and dopaminergic function, a poten-
tial mechanism for neuropsychiatric 
disorders. Proc. Natl. Acad. Sci. U.S.A. 
104, 8131–8136.
Seeman, P. (2002). Atypical antipsychot-
ics: mechanism of action. Can. J. 
Psychiatry 47, 27–38.
Seeman, P. (2006). Targeting the dopamine 
D2 receptor in schizophrenia. Expert 
Opin. Ther. Targets 10, 515–531.
Shi, L., Fatemi, S. H., Sidwell, R. W., and 
Patterson, P. H. (2003). Maternal 
influenza infection causes marked 
behavioral and pharmacological 
changes in the offspring. J. Neurosci. 
23, 297–302.
Swerdlow, N. R., Braff, D. L., Geyer, M. 
A., and Koob, G. F. (1986). Central 
dopamine hyperactivity in rats mim-
ics abnormal acoustic startle response 
in schizophrenics. Biol. Psychiatry 21, 
23–33.
Swerdlow, N. R., Braff, D. L., Masten, 
V. L., and Geyer, M. A. (1990). 
Schizophrenic-like sensorimotor gat-
ing abnormalities in rats following 
dopamine infusion into the nucleus 
accumbens.  Psychopharmacology 
(Berl.) 101, 414–420.
Swerdlow, N. R., Stephany, N., Wasserman, 
L. C., Talledo, J., Shoemaker, J., and 
Auerbach, P. P. (2003). Amphetamine 
effects on prepulse inhibition across-
species: replication and parametric 
extension. Neuropsychopharmacology 
28, 640–650.
Wakabayashi, T., Asano, M., Ishikawa, K., 
and Kishimoto, H. (1978). Mechanism 
of the formation of megamitochon-
dria by copper-chelating agents. V. 
Further studies on isolated meg-
amitochondria. Acta Pathol. Jpn. 28, 
215–223.
Wang, H., Xu, H., Dyck, L. E., and Li, X. 
M. (2005). Olanzapine and quetiapine 
protect PC12 cells from beta-amyloid 
peptide (25-35)-induced oxidative 
stress and the ensuing apoptosis. J. 
Neurosci. Res. 81, 572–580.
Weinberger, D. R. (1987). Implications 
of normal brain development for the 
pathogenesis of schizophrenia. Arch. 
Gen. Psychiatry 44, 660–669.
Westerink, B. H., de Boer, P., de Vries, J. B., 
Kruse, C. G., and Long, S. K. (1998). 
Antipsychotic drugs induce similar 
effects on the release of dopamine 
and noradrenaline in the medial pre-
frontal cortex of the rat brain. Eur. J. 
Pharmacol. 361, 27–33.
Woodward, N. D., Purdon, S. E., Meltzer, 
H. Y., and Zaid, D. H. (2005). A meta-
analysis of neuropsychological change 
to clozapine, olanzapine, quetiapine, 
and risperidone in schizophrenia. Int. 
J. Neuropsychopharmacol. 8, 1–16.
Xiao, L., Xu, H., Zhang, Y., Wei, Z., He, J., 
Jiang, W., Li, X., Dyck, L. E., Devon, 
R. M., Deng, Y., and Li, X. M. (2008). 
Quetiapine facilitates oligodendro-
cyte development and prevents mice 
from myelin breakdown and behav-
ioral changes. Mol. Psychiatry 13, 
697–708.
Xu, H., Qing, H., Lu, W., Keegan, D., 
Richardson, J. S., Chlan-Fourney, J., and 
Li, X. M. (2002). Quetiapine attenuates 
the immobilization stress-induced 
decrease of brain-derived neurotrophic 
factor expression in rat hippocampus. 
Neurosci. Lett. 321, 65–68.
Xu, H., Wang, H., Zhuang, L., Yan, B., 
Yu, Y., Wei, Z., Zhang, Y., Dyck, L. E., 
Richardson, S. J., He, J., Li, X., Kong, J., 
and Li, X. M. (2008). Demonstration 
of an anti-oxidative stress mecha-
nism of quetiapine: implications for 
the treatment of Alzheimer’s disease. 
FEBS J. 275, 3718–3728.
Xu, H., Yang, H. J., Zhang, Y., Clough, R., 
Browning, R., and Li, X. M. (2009). 
Behavioral and neurobiological 
changes in C57BL/6 mice exposed 
to cuprizone. Behav. Neurosci. 123, 
418–429.
Yang, H. J., Wang, H., Zhang, Y., Xiao, L., 
Clough, R. W., Browning, R., Li, X. M., 
and Xu, H. (2009). Region-specific 
susceptibilities to cuprizone-induced 
lesions in the mouse forebrain: 
Implications for the pathophysiology 
of schizophrenia. Brain Res. 1270, 
121–130.
Zhang, Y., Xu, H., Jiang, W., Xiao, L., Yan, 
B., He, J., Wang, Y., Bi, X., Li, X., Kong, 
J., and Li, X. M. (2008). Quetiapine 
alleviates the cuprizone-induced 
white matter pathology in the brain 
of C57BL/6 mouse. Schizophr. Res. 
106, 182–191.
Conﬂ  ict of Interest Statement: All authors 
declare that the research was conducted in 
the absence of any commercial or ﬁ  nancial 
relationships that could be construed as 
a potential conﬂ  ict of interest.
Received: 09 January 2010; paper pending 
published: 23 January 2010; accepted: 08 
February 2010; published online: 18 March 
2010.
Citation: Xu H, Yang H-J, McConomy B, 
Browning R and Li X-M (2010) Behavioral 
and neurobiological changes in C57BL/6 
mouse exposed to cuprizone: effects of antip-
sychotics. Front. Behav. Neurosci. 4:8. doi: 
10.3389/fnbeh.2010.00008
Copyright © 2010 Xu, Yang, McConomy, 
Browning and Li. This is an open-access 
article subject to an exclusive license agree-
ment between the authors and the Frontiers 
Research Foundation, which permits unre-
stricted use, distribution, and reproduc-
tion in any medium, provided the original 
authors and source are credited.